TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

PHASE3CompletedINTERVENTIONAL
Enrollment

616

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

February 18, 2022

Study Completion Date

June 18, 2022

Conditions
Hematologic NeoplasmsHemorrhageHematopoietic Stem Cell Transplantation
Interventions
DRUG

Tranexamic acid (TXA).

IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.

DRUG

Placebo

IV (saline) or oral placebo tablets

Trial Locations (27)

Unknown

Royal Adelaide Hospital, Adelaide

Royal Brisbane, Brisbane

Canberra Hospital, Canberra

Andrew Love Cancer Centre, Geelong

Alfred Hospital, Melbourne

Monash Health, Melbourne

St Vincent's Hospital, Melbourne

Victorian Comprehensive Cancer Centre, Melbourne

Royal North Shore Hospital, St Leonards

St Vincent's Hospital, Sydney

Westmead Hospital, Westmead

Royal United Hospital, Bath

Belfast City Hospital, Belfast

Heartlands Hospital, Birmingham

Queen Elizabeth Hospital, Birmingham

Bristol Haematology and Oncology Centre, Bristol

University Hospital Coventry, Coventry

Royal Devon and Exeter Hospital, Exeter

Beatson West of Scotland Cancer Centre, Glasgow

St James's Hospital, Leeds

Lincoln County Hospital, Lincoln

King's College Hospital, London

University College London Hospitals, London

Freeman Hospital, Newcastle

Churchill Hospital, Oxford

Derriford Hospital, Plymouth

Salisbury District Hospital, Salisbury

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

Monash University

OTHER

lead

NHS Blood and Transplant

OTHER_GOV

NCT03136445 - TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia | Biotech Hunter | Biotech Hunter